The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before ¹³¹I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, China’s first independently developed rhTSH agent was approved. Based on clinical experience and evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations to guide the appropriate use of rhTSH in clinical practice.

Objective:This study aimed to explore neurobiomarkers for schizophrenia relapse by comparing brain functional activity between first-diagnosed drug-na?ve schizophrenia (FDS) patients and relapsed schizophrenia (RS) patients.Methods:In this cross-sectional study, a total of 85 RS patients, 75 FDS patients, and 82 controls were recruited from the outpatient and inpatient departments of the Affiliated Brain Hospital of Nanjing Medical University between September 2018 and June 2020. All participants underwent magnetic resonance imaging scans. The fractional amplitude of low-frequency fluctuation (fALFF) was calculated to assess individual′s brain activity. The severity of psychiatric symptoms among patients with schizophrenia was evaluated using the Positive and Negative Syndrome Scale (PANSS). Voxel-based analysis of covariance (ANCOVA) with post-hoc two-sample t-tests was used to compare fALFF values among groups, and partial correlation analysis was employed to examine relationships between aberrant fALFF values and psychiatric symptoms. Results:The RS group demonstrated significantly higher negative symptom scores (21.5±9.1) compared to the FDS group (18.4±8.3; t=-2.28, P<0.05). Relative to the control group, the FDS group showed increased fALFF values in the cerebellum vermis 4/5 and the right putamen( t=4.45, 4.55, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05), while fALFF values were decreased in the right precentral gyrus/postcentral gyrus, bilateral precuneus, and right paracentral lobule ( t=-4.77--4.20, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05). The RS group exhibited increased fALFF values in the left cerebellum 9/10, bilateral cerebellum 6/8/Crus Ⅰ, right inferior temporal gyrus, right middle temporal gyrus, right inferior frontal gyrus (orbital part), and right putamen( t=4.78-5.44, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05), while decreased fALFF values were observed in the bilateral calcarine/cuneus, left superior medial frontal gyrus, right precuneus/cuneus, bilateral precuneus, and right precentral gyrus/postcentral gyrus ( t=-4.97--4.38, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05). Compared with the FDS group, the RS group showed increased fALFF values in the right cerebellum Crus Ⅰ (GRF-corrected, t=3.83, voxel-level P<0.001, cluster-level P<0.05). In the FDS group, correlation analysis revealed that fALFF values in the bilateral precuneus were negatively correlated with negative symptom scores, general psychopathology scores, and the PANSS total score ( r=-0.32, -0.26, -0.26,all P<0.05), while no such correlation was found in the RS group. Conclusions:RS patients exhibit more severe negative symptoms and more diffuse brain functional abnormalities compared to FDS patients, particularly affecting the default mode network and cerebellar regions. Functional alterations in the right cerebellum Crus Ⅰ and bilateral precuneus may serve as potential neuroimaging markers for identifying relapse in schizophrenia.

Objective:This study aimed to explore neurobiomarkers for schizophrenia relapse by comparing brain functional activity between first-diagnosed drug-na?ve schizophrenia (FDS) patients and relapsed schizophrenia (RS) patients.Methods:In this cross-sectional study, a total of 85 RS patients, 75 FDS patients, and 82 controls were recruited from the outpatient and inpatient departments of the Affiliated Brain Hospital of Nanjing Medical University between September 2018 and June 2020. All participants underwent magnetic resonance imaging scans. The fractional amplitude of low-frequency fluctuation (fALFF) was calculated to assess individual′s brain activity. The severity of psychiatric symptoms among patients with schizophrenia was evaluated using the Positive and Negative Syndrome Scale (PANSS). Voxel-based analysis of covariance (ANCOVA) with post-hoc two-sample t-tests was used to compare fALFF values among groups, and partial correlation analysis was employed to examine relationships between aberrant fALFF values and psychiatric symptoms. Results:The RS group demonstrated significantly higher negative symptom scores (21.5±9.1) compared to the FDS group (18.4±8.3; t=-2.28, P<0.05). Relative to the control group, the FDS group showed increased fALFF values in the cerebellum vermis 4/5 and the right putamen( t=4.45, 4.55, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05), while fALFF values were decreased in the right precentral gyrus/postcentral gyrus, bilateral precuneus, and right paracentral lobule ( t=-4.77--4.20, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05). The RS group exhibited increased fALFF values in the left cerebellum 9/10, bilateral cerebellum 6/8/Crus Ⅰ, right inferior temporal gyrus, right middle temporal gyrus, right inferior frontal gyrus (orbital part), and right putamen( t=4.78-5.44, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05), while decreased fALFF values were observed in the bilateral calcarine/cuneus, left superior medial frontal gyrus, right precuneus/cuneus, bilateral precuneus, and right precentral gyrus/postcentral gyrus ( t=-4.97--4.38, GRF-corrected, voxel-level P<0.001, cluster-level P<0.05). Compared with the FDS group, the RS group showed increased fALFF values in the right cerebellum Crus Ⅰ (GRF-corrected, t=3.83, voxel-level P<0.001, cluster-level P<0.05). In the FDS group, correlation analysis revealed that fALFF values in the bilateral precuneus were negatively correlated with negative symptom scores, general psychopathology scores, and the PANSS total score ( r=-0.32, -0.26, -0.26,all P<0.05), while no such correlation was found in the RS group. Conclusions:RS patients exhibit more severe negative symptoms and more diffuse brain functional abnormalities compared to FDS patients, particularly affecting the default mode network and cerebellar regions. Functional alterations in the right cerebellum Crus Ⅰ and bilateral precuneus may serve as potential neuroimaging markers for identifying relapse in schizophrenia.

Objective:To observe the correlation between blood cell-related inflammatory markers and diabetic retinopathy (DR).Methods:A cross-sectional study. From June 2020 to February 2022, the phase Ⅰ data of Beichen Eye Study in Tianjin Medical University Eye Hospital were included in the study. The research contents included questionnaires, routine systemic and ocular examinations, and laboratory blood cell-related indicators including mean platelet volume (MPV), platelet distribution width (PDW), neutrophils, and lymphocytes were performed. Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were calculated. The diagnosis and classification of DR referred to the international clinical classification standard of DR. Monocular or binocular DR was defined as DR patients. Participants were categorized into different groups based on whether they had diabetes and whether they had DR. The groups included the no-diabetes group, the diabetes without DR group, and the DR group. The Kruskal-Wallis H test was used for the comparison of quantitative data among multiple groups. Wilcoxon test was used for comparison between the two groups. The χ2 test was used to compare the categorical variables between groups. The variables was adjusted step by step, an unadjusted univariate model was built and the different parameters of the model Ⅰ, Ⅱ, Ⅲ were adjusted. The correlation between MPV, PDW, NLR, PLR, and DR in different models was analyzed by logistic regression. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic efficacy of different NLR models for DR. Results:A total of 3 328 subjects were recruited. Among them, 1 121 (33.68 %, 1 121/3 328) were males and 2 207 (66.32 %, 2 207/3 328) were females. The median age of the included participants was 61.84 (6.05) years. The no-diabetes group, the diabetes without DR group, and the DR group were 2 679, 476, and 173, respectively. There was no significant difference in MPV and PLR among the three groups ( H=5.98, 1.94; P=0.051, 0.379). However, compared with no-diabetes group and the diabetes without DR group, PDW and NLR in the DR group showed an upward trend. In model Ⅲ with completely adjusted related factors, NLR was an independent risk factor for DR in no-diabetes group and DR group [odds ratio ( OR)=1.440, 95% confidence interval ( CI) 1.087-1.920, P=0.041], diabetes without DR group and DR group [ OR=1.990, 95% CI 1.440-2.749, P<0.001]. The results of ROC curve analysis showed that the diagnostic efficiency of NLR model Ⅲ was the highest, the area under the curve was 0.751 (95% CI 0.706-0.796, P<0.001), the optimal cutoff value was 0.390, and the sensitivity and specificity were 74.3% and 64.8%, respectively. Conclusions:The NLR of the DR group is significantly higher than that of the no-diabetes group and diabetes without DR group. NLR is an independent risk factor for DR.

Schizophrenia is a kind of neurodevelopmental brain disease with genetic background.Cognitive impairment has always been concerned as the core symptom of schizophrenia, and genetic factors play an important role in the cognitive impairment process of schizophrenia.This paper intends to explore the relationship between various neurotransmitter systems and neurodevelopmental related genes and cognitive impairment in schizophrenia. With " schizophrenia" " cognitive" and " genetic" " dopamine" " glutamate" " serotonin" " norepinephrine" " acetylcholine" " neurodevelopmental" " genome-wide association studies" as key words, the author searched the English and Chinese literatures published from January 2001 to October 2019 in several databases, such as Pubmed, ScienceDirect, CNKI academic journal database, Wanfang academic journal database, and selected the literature that was in line with the review topic after a large number of readings.Meanwhile, the author applied the literature tracing method to search the references of the literature that had been reviewed. Finally, 29 related literatures were included, and it was found that cognitive impairment in schizophrenia is related to multiple neurotransmitter system genes and neurodevelopmental genes, and these genes have different mechanisms of action in the process of cognitive impairment. The occurrence and development of cognitive impairment in schizophrenia involve multiple gene effects. The genetic study of neurotransmitter system and neurodevelopmental level is helpful to explore the pathological mechanism of cognitive impairment in schizophrenia.Future research should focus on how the pathogenesis/candidate genes of schizophrenia affect the neurotransmitter system and neurodevelopmental circuits, and further elucidate the mechanism of genetic factors in the development of cognitive impairment in schizophrenia.